Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey

Simple item page
dc.contributor.authorSoyer, N
dc.contributor.authorAli, R
dc.contributor.authorTurgut, M
dc.contributor.authorHaznedaroglu, IC
dc.contributor.authorYilmaz, F
dc.contributor.authorAydogdu, I
dc.contributor.authorPir, A
dc.contributor.authorKarakus, V
dc.contributor.authorÖzgür, G
dc.contributor.authorKis, C
dc.contributor.authorCeran, F
dc.contributor.authorIlhan, G
dc.contributor.authorÖzkan, M
dc.contributor.authorAslaner, M
dc.contributor.authorInce, I
dc.contributor.authorYavasoglu, I
dc.contributor.authorGediz, F
dc.contributor.authorSönmez, M
dc.contributor.authorGüvenç, B
dc.contributor.authorÖzet, G
dc.contributor.authorKaya, E
dc.contributor.authorVural, F
dc.contributor.authorSahin, F
dc.contributor.authorTöbü, M
dc.contributor.authorDurusoy, R
dc.contributor.authorSaydam, G
dc.date.accessioned2025-04-10T10:37:26Z
dc.date.available2025-04-10T10:37:26Z
dc.description.abstractBackground/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.
dc.identifier.e-issn1303-6165
dc.identifier.issn1300-0144
dc.identifier.urihttp://hdl.handle.net/20.500.14701/43037
dc.language.isoEnglish
dc.titleEfficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu